Page 7 - சந்தேற மருந்துகள் வைத்திருத்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years in decline for time to stand (TTSTAND) velocity, and confirm safety and tolerability benefits of vamorolone over the 2.5-year follow up period. Long-term treatment with vamorolone resulted in significantly fewer corticosteroid-associated adverse events than reported in other clinical trials with other steroids.

Switzerland generalUnited statesUnited kingdomEric hoffmanEva kaliasReveragen biopharmaDario eklundReveragen biopharma incSanthera pharmaceuticalsInternational neuromuscular research groupNational institutes of healthMuscular dystrophy association united statesHead external communicationsEuropean commission horizonDuchenne research fundFoundation to eradicate duchenne